



Translational medicine in Catalonia: the case of liver oncology

Josep M. Llovet¹⁻³

¹Barcelona-Clínic Liver Cancer Group (BCLC), Unitat d'Hepatologia, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona.

²Mount Sinai Liver Cancer Program, Division of Liver Diseases. Icahn School of Medicine at Mount Sinai, New York, USA.

³Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona.

Abstract. Biomedical research has improved during the last decade in Catalonia, which is currently a well-recognized international biomedical scientific hub. The policy of head-hunting and attraction of talent fostered by the Catalan Government through the ICREA Professorship initiative has been successful. In 2006, I was appointed as ICREA Professor and started a research group in Translational research in liver oncology at IDIBAPS-Hospital Clínic in Barcelona. This appointment was possible due to a suitable environment in this institution, both regarding liver and translational medical research. This article summarizes some of the major advancements in translational medicine, liver research and translational hepatic oncology achieved during the last decade.

Resum. La recerca biomèdica ha millorat notablement a Catalunya durant la darrera dècada de tal manera que el nostre país es considera un pol de recerca internacionalment reconegut. Les polítiques endegades pel Govern de la Generalitat amb la creació del programa ICREA per a l'atracció de talent internacional han estat molt exitoses. En el meu cas, vaig tornar l'any 2006 de Nova York per organitzar un grup de recerca translacional en oncologia hepàtica al IDIBAPS-Hospital Clínic de Barcelona. Els avenços del nostre grup han estat possibles atès l'entorn científic que ofereix la institució pel que fa a recerca en malalties hepàtiques i en recerca translacional. El present article analitza alguns dels avenços en recerca translacional, recerca hepàtica i recerca translacional en oncologia hepàtica assolits al nostre país en la darrera dècada.

Keywords: –

Correspondence:

Josep M. Llovet
<https://www.icrea.cat/Web/ScientificStaff/josep-m-llovet-bayer-387>;
<http://translationalhcc.idibaps.org>

Translational medicine in Catalonia

Translational medicine has achieved major goals during the last decade in Catalonia. We understand translational medicine as the branch of the biomedical field aimed to

translate discoveries from basic research to the clinical setting in order to benefit patients¹. Originally, the concept of translational medicine was captured by the motto *from bench to bedside*, but I rather prefer to describe it as *from the patient to the lab and back to the patient*². In most ins-

tances, translational medicine equals to the modern clinical research. In order to put this concept in context in Catalonia, we need to take into account the following facts:

a) Advancements produced in translational medicine represent, in my view, the most substantial and critical research produced in biomedical centers in Catalonia, particularly by those centers associated with clinical hospitals, such as IDIBAPS (associated to Hospital Clínic of Barcelona), IDIBELL (associated to Hospital Bellvitge) and VHIR/ VHIO (associated to Hospital Vall d'Hebrón).

b) Recent data from the Catalan Government – reported in *Science* on Sept 29th, 2017- between 2007 and 2015 Catalonia has obtained 210 *European Research Council* (ERC) projects, with a total of 334M€ of funding. Some awarded projects are substantially translational in nature.

c) Most of the so called *Top 1% cited investigators* worldwide working in Catalan institutions are conducting translational research in medicine.

d) At least 3 Universities in Barcelona are offering studies in biomedical translational research. Among those, I am directing the *Official Master in Translational Medicine*, in the Faculty of Medicine, University of Barcelona.

To further understand the depth of the achievements in translational medicine in our country, I am summarizing some of the ones that have been generated in my own institution, IDIBAPS-Hospital Clínic.

a) Autoimmune encephalitis: Discovery of this new entity -autoimmune encephalitis- and characterization of the NMDA receptor as the target of the immune system. This advancement has re-defined the molecular basis of some mental disorders, thus providing the rationale for a novel therapeutic approach³.

b) Chronic lymphocytic leukemia (CLL): Novel classification of CLL and discovery of the landscape of oncogenic mutations as potential targets for therapies⁴.

c) Cancer of unknown origin: This entity is causing thousands of deaths worldwide. A recent study from IDIBELL/IDIBAPS demonstrates that by exploring the methylome of the neoplastic cells it is possible to identify the primary origin of the neoplasm and optimize the treatment⁵.

d) Alzheimer disease: Identification of amyloid-related biomarkers in the asymptomatic phase of Alzheimer's disease. This discovery paves the path towards primary prevention of this devastating disease⁶.

e) Bipolar disorder: By genome-wide analysis the authors identified a DNA polymorphism able to predict response to lithium for prevention of recurrence of bipolar disorder⁷.

Liver research at IDIBAPS-Hospital Clínic

The Liver Unit at Hospital Clínic-IDIBAPS is one of the 3-4 international groups with a higher impact in advancing the understanding of the pathogenesis and treatment of liver diseases during the last decades. This Unit was founded and led by Dr Joan Rodés, a giant in the world of Hepatology. He was also founder of the *European Association for the Study of the Liver* (EASL) and Editor-in-chief of *Journal of Hepatology*. His outstanding scientific production – *h index* of 128- was acknowledged with several national and international awards. He had the vision in 1970-80 to organize the research in liver disease according to specific areas (ascites, portal hypertension, hepatitis, liver cancer and transplant), assigning the leadership of each one to different faculties. An overview of the main contributions has been reported elsewhere^{8,9}, and are summarized as follows:

a) Staging and treatment of hepatocellular carcinoma (HCC): The proposal of the Barcelona-Clínic system (BCLC) for staging and treatment allocation^{10,11}, has been adopted by European and US clinical practice guidelines of management of HCC. This group has also provided the evidence for establishing chemoembolization as standard of care in intermediate HCC¹², and led the international randomized trials supporting the use of sorafenib¹³ and regorafenib¹⁴ in first and second line treatments in advanced cases.

b) Pathogenesis and treatment of ascites: Characterization of the mechanisms involved in the development of liver-related complications, such as ascites¹⁵. In addition, the authors led several studies supporting the use of albumin infusion to prevent hepato-renal syndrome after large volume paracentesis¹⁶ and to improve survival of spontaneous bacterial peritonitis episodes¹⁷.

c) Treatment of portal hypertension: The group described the pathophysiological mechanisms of portal hypertension and the efficacy of pharmacological¹⁸ and non-pharmacological therapeutic approaches¹⁹.

d) Treatment of hepatitis C infection: The treatment of hepatitis C infection has revolutionized the field during the last 5 years. Nowadays, up to 90% of patients achieve sustained virological responses with the new drug antiviral treatments. The group has contributed to the understanding and management of this infection in the context of chronic liver disease²⁰ and after liver transplantation²¹.

Other important achievements have been reported in the areas of liver transplantation and cholestatic disorders.

Translational research in liver oncology

In 2006, and taking advantage of the outstanding research environment in the setting of the Liver Unit and the BCLC group, I created the group of *translational research in liver oncology* at the IDIBAPS- Hospital Clínic. This occurred after spending 3 years at the Mount Sinai School of Medicine in Nova York, where I created the Liver Cancer Program. Thus, after my return to Europe I retained the position of Director of this program in NYC, which is currently the only NCI recognized liver cancer program in the US. As a result of these two outstanding positions, our group has been able to produce more than 200 research articles in peer-reviewed journals (mean impact factor/article: 18 points). This research has been supported by competitive (including EU and NIH grants) and non-competitive funding of around 20M€. I can proudly say that I have been able to mentor 35 physicians and scientists interested in translational research in liver oncology. As a result of all this effort we have made the following contributions:

a) **Establishment of the molecular classification of HCC.** We proposed a molecular classification of HCC after analyzing the genome of >1000 cases^{22,23}. More recently, we complemented the information by providing the characterization of the immune class of HCC, which is expected to respond to checkpoint inhibitors, and the exclusion class, which is expected to be primary resistant to immune therapies²⁴.

b) **Characterization of oncogenes and signaling pathways involved in the pathogenesis of HCC.** As a result of several studies we defined that the main molecular aberrations occurring in HCC are nowadays non actionable, and only around 30% could be potentially treated with effective drugs^{25,26}. From a more clinical perspective, some early clinical trials are currently ongoing based upon these discoveries.

c) **Establishment of the molecular characterization of intrahepatic colangiocarcinoma (iCCA) and discovery of novel oncogenic drivers.** We proposed a novel classification of iCCA and discovered a novel oncogene resulting from a translocation leading to a fusion protein involving FGFR2^{27,28}. These results have been translated in early clinical trials.

d) **Involvement in the design of clinical practice guidelines for the management of HCC.** I have participated in developing the Clinical Practice Guidelines of management of HCC supported by the EASL (2001, 2012 and 2018) and ESMO (2018).

After analyzing the research achievements described above in the area of translational medicine, liver research and translational liver oncology, it seems obvious to me that successful research is achieved by scientist with a unique fingerprint: a) **talented leadership and group**, b) adequate **environment** to facilitate conducting high-end research, c) hard **work capacity**, this is a constant in all cases, and d) focus on a specific area.

References

- Butler D. (2008) Translational research: Crossing the valley of death. *Nature* 453:840–2.
- Llovet JM, editor (2016) *Handbook of Translational Medicine*. Barcelona: Universitat de Barcelona.
- Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. (2008) Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. *Lancet Neurol* 7:1091–8.
- Puente XS, Pinyol M, Quesada V, Conde L, Ordóñez GR, Villamor N, et al. (2011) Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. *Nature* 475:101–5.
- Moran S, Martínez-Cardús A, Sayols S, Musulén E, Balañá C, Estival-Gonzalez A, et al. (2016) Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. *Lancet Oncol* 17:1386–95.
- Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. (2013) Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. *Lancet Neurol* 12:207–16.
- Hou L, Heilbronner U, Degenhardt F, Adli M, Akiyama K, Akula N, et al. (2016) Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. *Lancet* 387:1085–93.
- Gomis R, Pardo R, Trilla A, editors (2017) *Homenaje a Juan Rodés. Trayectoria y facetas de un visionario*. Barcelona: Fundación BBVA.
- Bruguera i Cortada M (2003) *La Unidad de Hepatología del Hospital Clínic de Barcelona. La historia de una aventura*. Barcelona: Col•legi Oficial de Metges de Barcelona.
- Llovet J, Brú C, Bruix J (1999) Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification. *Semin Liver Dis* 19:329–38.
- Bruix J, Reig M, Sherman M (2016) Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. *Gastroenterology* 150:835–53.
- Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, et al. (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. *Lancet* 359:1734–9.
- Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-FJ, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med* 359:378–90.
- Bruix J, Qin S, Merle P, Granito A, Huang Y-H, Bodoky G, et al. (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 389:56–66.
- Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. (1996) Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. *Hepatology* 23:164–76.

16. Ginès P, Arroyo V, Vargas V, Planas R, Casafont F, Panés J, et al. (1991) Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites. *N Engl J Med* 325:829–35.
17. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, et al. (1999) Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. *N Engl J Med* 341:403–9.
18. D'Amico G, Pagliaro L, Bosch J (1995) The treatment of portal hypertension: a meta-analytic review. *Hepatology* 22:332–54.
19. García-Pagán JC, Caca K, Bureau C, Laleman W, Appenrodt B, Luca A, et al. (2010) Early use of TIPS in patients with cirrhosis and variceal bleeding. *N Engl J Med* 362:2370–9.
20. Forns X, Ampurdanès S, Llovet JM, Aponte J, Quintó L, Martínez-Bauer E, et al. (2002) Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. *Hepatology* 36:986–92.
21. Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R, et al. (2014) An Interferon-free Antiviral Regimen for HCV after Liver Transplantation. *N Engl J Med* 371:2375–82.
22. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, et al. (2008) Gene expression in fixed tissues and outcome in hepatocellular carcinoma. *N Engl J Med* 359:1995–2004.
23. Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B, et al. (2008) Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. *Cancer Res* 68:6779–88.
24. Sia D, Jiao Y, Martinez-Quetglas I, Kuchuk O, Villacorta-Martin C, Castro de Moura M, et al. (2017) Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. *Gastroenterology* [Epub].
25. Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y, Toffanin S, et al. (2012) Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. *Gastroenterology* 143:1660–9.e7.
26. Schulze K, Imbeaud S, Letouze E, Alexandrov L, Calderaro J, Rebouissou S, et al. (2015) Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. *Nat Genet* 47:505–11.
27. Saha SK, Parachoniak C a., Ghanta KS, Fitamant J, Ross KN, Najem MS, et al. (2014) Mutant IDH inhibits HNF-4 α to block hepatocyte differentiation and promote biliary cancer. *Nature* 513:2310010.
28. Sia D, Losic B, Moeini A, Cabellos L, Hao K, Revill K, et al. (2015) Massive parallel sequencing uncovers actionable FGFR2–PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. *Nat Commun* 6:6087.